Story HighlightsTelix Pharmaceuticals Updates Director’s Interest in Securities
- Telix Pharmaceuticals focuses on oncology with molecularly targeted radiation products.
- Director Dr. Behrenbruch acquires PSARs and SRs, aligning compensation with performance.
Telix Pharmaceuticals ( TLX -0.35% ▼ ) has shared an update.
Telix Pharmaceuticals has announced a change in the director’s interest, specifically for Dr. Christian Behrenbruch, who has acquired 166,483 Performance Share Appreciation Rights (PSARs) and 2,595 Deferred Share Rights (SRs) as part of his remuneration package. This change reflects the company’s commitment to aligning executive compensation with performance goals, potentially impacting the company’s operational focus and stakeholder interests by incentivizing leadership to achieve significant revenue milestones.
The most recent analyst rating on TLX -0.35% ▼ stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited operates in the biotechnology industry, focusing on the development of diagnostic and therapeutic products using molecularly targeted radiation. The company primarily targets the oncology market, aiming to improve cancer diagnosis and treatment through innovative radiopharmaceuticals.
Average Trading Volume: 1,600,992
Technical Sentiment Signal: Buy
Current Market Cap: A$8.66B
Telix Pharmaceuticals Updates Director’s Interest in...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$25.75 |
Change
0.240(0.94%) |
Mkt cap ! $8.709B | |||
| Open | High | Low | Value | Volume |
| $25.51 | $26.25 | $25.51 | $31.79M | 1.227M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 116 | $25.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $25.80 | 1607 | 1 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| TLX (ASX) Chart |